Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...
Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, ...
RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...
Stocktwits on MSN
NVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna again
Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...
In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...
FDA officials stopped publication of studies backing COVID-19 and shingles vaccine safety, citing data concerns.
Katalin Karikó, PhD, co-inventor on mRNA-related applications of non-immunogenic, nucleoside-modified RNA for vaccines and ...
Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious ...
Pfizer has been leaning on recently acquired products to offset a looming patent cliff.
You mentioned in a recent column that prospective randomized controlled trials (RCTs) are a powerful type of study. Can you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results